Pennsylvania is currently home to 3308 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NAVA vs. CMV Crossover in Severe BPD
NCT04821453
Recruiting
This prospective, unblinded, pilot randomized cross-over trial of 2 modes of mechanical ventilation will compare measures of pulmonary mechanics, respiratory gas exchange, and patient comfort between conventional flow triggered mechanical ventilation and neurally adjusted ventilatory assist (NAVA) among 20 prematurely born infants and young children receiving invasive respiratory support for severe bronchopulmonary dysplasia (BPD).
Gender:
ALL
Ages:
24 months and below
Trial Updated:
11/11/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist, Mechanical Ventilation
Register for Updates
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
NCT04469530
Recruiting
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/11/2024
Locations: Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania
Conditions: Solid Tumor
Register for Updates
D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
NCT04411199
Recruiting
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/11/2024
Locations: Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania
Conditions: Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Register for Updates
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385
Recruiting
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Register for Updates
Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study)
NCT06152237
Recruiting
The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is up to 6 years.
Gender:
FEMALE
Ages:
Between 5 years and 8 years
Trial Updated:
11/10/2024
Locations: Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania
Conditions: Rett Syndrome
Register for Updates
Virtual Peer Coaching in Manual Wheelchair Skills
NCT06295146
Recruiting
The objective of this study is to determine the effectiveness of remote manual wheelchair skills training program. First, peer coaches will be enrolled and trained. Then, trainees will be enrolled into one of three interventions: intervention with remote feedback (Group 1), wait list control group (Group 2), and structured self-study (Group 3).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Wheelchair, Paraplegia
Register for Updates
Neurophysiologic Biomarkers in Rett Syndrome
NCT05932589
Recruiting
The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are: * Do these biomarkers change during clinical changes in individuals with RTT? * Are biomarkers stable over time in clinically stable individuals? * Do these biomarkers correlate with severity of RTT? Participants will be asked to undergo an electroencephalogram (EEG) with measurements of Evoked Potentials (EP) to measure electrical activity... Read More
Gender:
FEMALE
Ages:
Between 1 year and 18 years
Trial Updated:
11/08/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Rett Syndrome, RTT, Rett Syndrome, Atypical
Register for Updates
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493
Recruiting
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Register for Updates
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378
Recruiting
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, Paoli, Pennsylvania
Conditions: Lung Cancer, Non-Small Cell
Register for Updates
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
NCT05392114
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/08/2024
Locations: Ionis Investigative Site, Hershey, Pennsylvania
Conditions: Hereditary Angioedema
Register for Updates
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051
Recruiting
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, Philadelphia, Pennsylvania
Conditions: Neoplasms
Register for Updates
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
NCT05263050
Recruiting
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
Register for Updates